CoChat
Sign Up
Cited by 123

The DOI matches its Crossref record.

TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state

Herling, M, Patel, K A, Khalili, J, Schlette, E, Kobayashi, R, Medeiros, L J, Jones, D·2006·Leukemia
DOI 10.1038/sj.leu.2404017
Open this paper in CoChat — free account

Abstract

Expression of the human oncogene TCL1 in transgenic mice produces B-cell tumors that resemble chronic lymphocytic leukemia (CLL) suggesting its role in B-cell tumorigenesis. To clarify the expression pattern and regulation of TCL1 in CLL, we assessed 213 primary tumors by immunohistochemistry (IHC), flow-cytometry and/or Western blot, using a new monoclonal antibody. TCL1 protein was detectable in the majority of CLL (90% by IHC) but showed marked variations across cases with virtual absence in approximately 10% of tumors. Higher TCL1 levels correlated with markers of the 'pre-germinal center' CLL subtype including unmutated VH status (P=0.005), ZAP70 expression (P=0.007), and presence of chromosome 11q22-23 deletions (P=0.04). Intratumoral heterogeneity in TCL1 levels was also prominent and explained in part by markedly lower TCL1 expression in proliferating tumor cells. In vitro exposure of CLL cells to interleukin-4 (but not other growth factors) produced progressive and irreversible decrease in TCL1 protein levels in association with the onset of proliferation. TCL1 expression patterns in CLL are complex and highly dynamic and appear to reflect both the histogenetic subtypes of the disease and the growth parameters of individual tumors. The observed regulation pattern suggests that TCL1 may exert its effects predominantly in the unmutated/ZAP70-positive tumor subset.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.leu.2404017

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 21

  1. Brito-Babapulle V, Catovsky D . Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia. Cancer Genet Cytogenet 1991; 55: 1–9. · DOI
  2. Virgilio L, Isobe M, Narducci MG, Carotenuto P, Camerini B, Kurosawa N et al. Chromosome walking on the TCL1 locus involved in T-cell neoplasia. Proc Natl Acad Sci USA 1993; 90: 9275–9279. · DOI
  3. Virgilio L, Narducci MG, Isobe M, Billips LG, Cooper MD, Croce CM et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994; 91: 12530–12534. · DOI
  4. Isobe M, Russo G, Haluska FG, Croce CM . Cloning of the gene encoding the delta subunit of the human T-cell receptor reveals its physical organization within the alpha-subunit locus and its involvement in chromosome translocations in T-cell malignancy. Proc Natl Acad Sci USA 1988; 11: 3933–3937. · DOI
  5. Russo G, Isobe M, Gatti R, Finan J, Batuman O, Huebner K et al. Molecular analysis of a t(14;14) translocation in leukemic T-cells of an ataxia telangiectasia patient. Proc Natl Acad Sci USA 1989; 86: 602–606. · DOI
  6. Virgilio L, Lazzeri C, Bichi R, Nibu K, Narducci MG, Russo G et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA 1998; 95: 3885–3889. · DOI
  7. Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991; 78: 3269–3274. · DOI
  8. Soulier J, Pierron G, Vecchione D, Garand R, Brizard F, Sigaux F et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2001; 31: 248–254. · DOI
  9. Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D . A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004; 104: 328–335. · DOI
  10. Narducci MG, Fiorenza MT, Kang SM, Bevilacqua A, Di Giacomo M, Remotti D et al. TCL1 participates in early embryonic development and is overexpressed in human seminomas. Proc Natl Acad Sci USA 2002; 99: 11712–11717. · DOI
  11. Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D . TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 2003; 101: 5007–5009. · DOI
  12. Hoyer KK, Herling M, Bagrintseva K, Dawson DW, French SW, Renard M et al. T cell leukemia-1 modulates TCR signal strength and IFN-{gamma} levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol 2005; 175: 864–873. · DOI
  13. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 2000; 60: 2095–2100.
  14. Nakayama I, Murao S, Kitazawa S, Azumi A, Yamamoto M, Maeda S . Activation of the TCL1 protein in B cell lymphomas. Pathol Int 2000; 50: 191–199. · DOI
  15. Said JW, Hoyer KK, French SW, Rosenfelt L, Garcia-Lloret M, Koh PJ et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest 2001; 81: 555–564. · DOI
  16. Roos J, Hennig I, Schwaller J, Zbaren J, Dummer R, Burg G et al. Expression of TCL1 in hematologic disorders. Pathobiology 2001; 69: 59–66. · DOI
  17. Teitell M, Damore MA, Sulur GG, Turner DE, Stern MH, Said JW et al. TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues. Proc Natl Acad Sci USA 1999; 96: 9809–9814. · DOI
  18. Fink SR, Paternoster SF, Smoley SA, Flynn HC, Geyer SM, Shanafelt TD et al. Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia. Leuk Res 2005; 29: 253–262. · DOI
  19. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955–6960. · DOI · Paper page
  20. Hoyer KK, French SW, Turner DE, Nguyen MT, Renard M, Malone CS et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 2002; 99: 14392–14397. · DOI
  21. Ottensmeier CH, Thompsett AR, Zhu D, Wilkins BS, Sweetenham JW, Stevenson FK . Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression. Blood 1998; 91: 4292–4299. · DOI

Cited by

Metadata

Authors
Herling, M., Patel, K. A., Khalili, J., Schlette, E., Kobayashi, R., Medeiros, L. J., & Jones, D.
Venue
Leukemia
Publisher
Springer Science and Business Media LLC
Published
2005-12-08
Volume
20
Issue
2
Pages
280-285
ISSN
  • 0887-6924
  • 1476-5551
DOI
10.1038/sj.leu.2404017
Cited by
123
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review